Oruka Therapeutics’ (ORKA) “Buy” Rating Reaffirmed at HC Wainwright (2025)

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $45.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 140.77% from the stock’s previous close.

Several other equities analysts have also weighed in on the stock. TD Cowen started coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They issued a “buy” rating on the stock. Lifesci Capital started coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price objective on the stock. Leerink Partners assumed coverage on shares of Oruka Therapeutics in a research report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 price target on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Oruka Therapeutics currently has an average rating of “Buy” and a consensus price target of $43.17.

View Our Latest Analysis on Oruka Therapeutics

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $18.69 on Monday. The stock’s fifty day moving average price is $25.86. Oruka Therapeutics has a 1 year low of $18.20 and a 1 year high of $53.88. The company has a market capitalization of $654.15 million, a price-to-earnings ratio of -2.98 and a beta of 0.87.

Institutional Investors Weigh In On Oruka Therapeutics

A number of large investors have recently bought and sold shares of the company. Geode Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $343,000. The Manufacturers Life Insurance Company bought a new position in Oruka Therapeutics in the 3rd quarter valued at approximately $1,037,000. Wellington Management Group LLP bought a new position in Oruka Therapeutics during the 3rd quarter worth approximately $2,013,000. Janus Henderson Group PLC bought a new position in Oruka Therapeutics during the 3rd quarter worth approximately $5,840,000. Finally, Redmile Group LLC bought a new position in Oruka Therapeutics during the 3rd quarter worth approximately $10,091,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

(Get Free Report)

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.

Recommended Stories

• Five stocks we like better than Oruka Therapeutics
• Find and Profitably Trade Stocks at 52-Week Lows
• Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
• What is a Low P/E Ratio and What Does it Tell Investors?
• Why Warren Buffett Is Selling: A Look at His Latest Market Moves
• What is an Earnings Surprise?
• Why Amazon Shares May Never Trade Below $200 Again

Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.